Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
open image in gallery An injection pen of Zepbound, Eli Lilly’s weight loss drug, is seen next to boxes of Novo Nordisk’s Wegovy earlier this year. Novo Nordisk said it would wait for the ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...